Nasdaq:US$13.27 (+0.05) | HKEX:HK$21.95 (+0.90) | AIM:£2.09 (-0.04)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors